Not a good buy right now for an impatient buyer: the tape is bullish short-term, but the latest quarter fundamentals are severely negative (large net loss/EPS collapse) and there are no near-term catalysts.
If you already own it, the chart can still work for a momentum hold, but as a fresh entry here the risk/reward is not compelling at ~8.97 with RSI stretched and resistance overhead near 9.19–9.52.
Insider buying is a meaningful positive signal, but it’s not enough to offset the magnitude of the earnings deterioration in the latest reported quarter.
Technical Analysis
Trend: Bullish structure with moving averages stacked positively (SMA_5 > SMA_20 > SMA_200), suggesting an ongoing uptrend.
Momentum: MACD histogram is above 0 (bullish) but positively contracting, implying upside momentum is fading rather than accelerating.
RSI: RSI_6 at ~72.44 (effectively overbought/extended), which increases the odds of a near-term pullback or chop rather than a clean continuation.
Key levels: Pivot 8.662; support S1 8.131 (then S2 7.803). Resistance R1 9.193 (then R2 9.521). At ~8.97, price is closer to resistance than support, which is weaker for an immediate buy.
Pattern-based expectation: Similar-pattern stats imply modest upside only (next day ~0.9%, next week ~0.27%, next month ~1.3%), not a strong edge for a “buy now” decision.
Insiders are buying aggressively (buying amount up ~1664% over the last month), often a constructive signal for confidence or perceived undervaluation.
Technical trend remains bullish via moving-average alignment.
No negative news flow in the last week (no fresh headline overhang).
Neutral/Negative Catalysts
and upside is capped by nearby resistance (9.19–9.52).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 22.487M, down ~9.07% YoY (top-line contraction).
Net income: -45.585M, down ~3489% YoY (sharp deterioration into a large loss).
EPS: -3.01, down ~2836% YoY (major profitability collapse).
Overall: The quarter shows severe earnings/quality stress; this materially weakens the case for buying immediately despite the improved chart.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating changes or price target updates were provided in the data.
Wall Street-style cons (inferred from provided data): steep YoY revenue decline and a very large net loss/EPS collapse in 2025/Q3, with no near-term catalysts indicated—fundamentals currently dominate the risk picture.
Wall Street analysts forecast FGBI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FGBI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast FGBI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FGBI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
